USCB Financial (USCB)
(Delayed Data from NSDQ)
$12.02 USD
-0.08 (-0.66%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $12.03 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
USCB 12.02 -0.08(-0.66%)
Will USCB be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for USCB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for USCB
Why USCB Financial (USCB) Might be Well Poised for a Surge
USCB Financial Holdings, Inc. (USCB) Q1 Earnings and Revenues Top Estimates
USCB: What are Zacks experts saying now?
Zacks Private Portfolio Services
USCB Financial Holdings, Inc. (USCB) Misses Q4 Earnings and Revenue Estimates
First Community Bancshares (FCBC) Q4 Earnings and Revenues Surpass Estimates
Synovus Financial (SNV) Misses Q4 Earnings and Revenue Estimates
Other News for USCB
U.S. community bank earnings expected to fall by about 12% this year - report
Axxes Capital Appoints Maria C. Alonso to Board of Directors
USCB Financial Holdings, Inc. Class A (USCB) Receives a Buy from KBW
Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2024 Update
David Abrams Exits Teva Pharmaceutical in Q1 2024, Reflecting Strategic Portfolio Adjustments